A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Susana InogésSonia TejadaAscensión López-Díaz de CerioJaime Gállego Pérez-LarrayaJaime EspinósMiguel Angel IdoatePablo Daniel DomínguezReyes García de EulateJavier AristuMaurizio BendandiFernando PastorMarta AlonsoEnrique AndreuFelipe Prósper CardosoRicardo Díez VallePublished in: Journal of translational medicine (2017)
Our results suggest that the addition of tumor lysate-pulsed autologous DCs vaccination to tumor resection and combined radio-chemotherapy is feasible and safe. A multicenter randomized clinical trial is warranted to evaluate the potential survival benefit of this therapeutic approach. Trial registration This phase-II trial was registered as EudraCT: 2009-009879-35 and ClinicalTrials.gov Identifier: NCT01006044 retrospectively registered.
Keyphrases
- newly diagnosed
- dendritic cells
- bone marrow
- locally advanced
- ejection fraction
- minimally invasive
- cell therapy
- open label
- prognostic factors
- clinical trial
- double blind
- randomized controlled trial
- phase iii
- risk assessment
- platelet rich plasma
- single molecule
- study protocol
- squamous cell carcinoma
- cross sectional
- radiation therapy
- mesenchymal stem cells
- atrial fibrillation
- placebo controlled
- acute coronary syndrome
- rectal cancer
- quantum dots
- human health
- chemotherapy induced